13th European Cancer Conference — ECCO 13

From Basic Research to Practical Clinical Tools; 30 October–3 November 2005; Paris, France
  • Andrea Bothwell
Meeting Report


Bevacizumab Gemcitabine Trastuzumab Irinotecan Capecitabine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Miller K, Wang M, Gralow J, et al. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100) [abstract]. Eur J Cancer Suppl 2005 Oct; 3 (2): 77Google Scholar
  2. 2.
    Bianchi G, Loibl S, Zamagni C, et al. A phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer [abstract 276]. Eur J Cancer Suppl 2005 Oct; 3 (2): 78Google Scholar
  3. 3.
    Stein SH, Gomez HL, Chavez MA, et al. Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISHamplified advanced or metastatic breast cancer [abstract 277]. Eur J Cancer Suppl 2005 Oct; 3 (2): 78Google Scholar
  4. 4.
    Storniolo AM, Burris III HA, Pegram MD, et al. Phase I study of lapatinib (GW572016) in combination with trastuzumab in advanced ErbB2-positive breast cancer [abstract 278]. Eur J Cancer Suppl 2005 Oct; 3 (2): 78Google Scholar
  5. 5.
    Gluz O, Ting E, Mohrmann S, et al. Basal-like subtype of breast carcinoma predicts poor clinical outcome in patients with high-risk breast cancer treated with high-dose or dose-dense chemotherapy: results of multivariate analysis from the WSG-AM-01 phase III trial [abstract 279]. Eur J Cancer Suppl 2005 Oct; 3 (2): 79Google Scholar
  6. 6.
    Dodwell D. Time to response: a comparison of fulvestrant with anastrozole [abstract 280]. Eur J Cancer Suppl 2005 Oct; 3 (2): 79Google Scholar
  7. 7.
    Untch M. Herceptin after adjuvant chemotherapy significantly improves diseasefree survival in HER2-positive early breast cancer: HERA trial interim analysis [abstract PS4]. Eur J Cancer Suppl 2005 Oct; 3 (4): 4CrossRefGoogle Scholar
  8. 8.
    Romond EH, Perez EA, Bryant J, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER2-positive operable breast cancer: combined analysis of NSABP B-31 and NCCTG N9831 [abstract 263]. Eur J Cancer Suppl 2005 Oct; 3 (2): 73Google Scholar
  9. 9.
    Perez E, Suman VJ, Davidson N, et al. Concurrent trastuzumab and paclitaxel treatment improves disease-free survival in resected HER2-positive breast cancer: NCCTG N9831 interim analysis [abstract 264]. Eur J Cancer Suppl 2005 Oct; 3 (2): 74Google Scholar
  10. 10.
    Slamon D, Eiermann W, Robert N, et al. BCIRG 006: superior cardiac safety of adjuvant docetaxel, carboplatin and trastuzumab compared to doxorubicin and cyclophosphamide followed by TH in patients with early stage breast cancer and altered HER2 gene [abstract 265]. Eur J Cancer Suppl 2005 Oct; 3 (2): 74Google Scholar
  11. 11.
    Ingle J, Goss P, Dongsheng T. NCIC CTG MA17: increasing benefit of letrozole with longer duration of treatment as measured by the hazard ratio of disease recurrence over time [abstract 266]. Eur J Cancer Suppl 2005 Oct; 3 (2): 74Google Scholar
  12. 12.
    Goss P, Ingle J, Dongsheng T, et al. 17 Collaborative Trialists. Oral NCIC CTG MA17: disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor [abstract 267]. Eur J Cancer Suppl 2005 Oct; 3 (2): 74–5Google Scholar
  13. 13.
    Duffy S, ATAC Trialists’ Group. Gynaecological adverse events and hysterectomies in the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial [abstract 268]. Eur J Cancer Suppl 2005 Oct; 3 (2): 75Google Scholar
  14. 14.
    Women may avoid the life-threatening side effects associated with some hormonal early breast cancer therapies by initiating treatment with arimidex?. Press release 2005 Nov 1 [online]. Available from URL: [Accessed 2005 Nov 28]
  15. 15.
    Herrstedt J, Plaza J, Schmalfeldt B, et al. Paclitaxel-carboplatin-gemcitabine versus paclitaxel-carboplatin as first line treatment in women with ovarian cancer: a randomized phase III GCIG Intergroup study (AGO-OVAR9, GINECO-TCG, NSGO-OC-0102) [abstract 902]. Eur J Cancer Suppl 2005 Oct; 3 (2): 259Google Scholar
  16. 16.
    Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of single agent pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status [abstract 903]. Eur J Cancer Suppl 2005 Oct; 3 (2): 259–60Google Scholar
  17. 17.
    Veerasarn V, Lorvidhaya V, Suntornpong N, et al. A randomized phase III trial of concurrent chemoradiation in locally advanced cervical cancer: preliminary results [abstract 905]. Eur J Cancer Suppl 2005 Oct; 3 (2): 260Google Scholar
  18. 18.
    Oza AM, Elit L, Biagi J, et al. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or recurrent endometrial cancer — NCIC CTG IND 160 [abstract 907]. Eur J Cancer Suppl 2005 Oct; 3 (2): 261Google Scholar
  19. 19.
    Glimelius B, Sørbye H, Balteskard L, et al. A randomised phase III multicenter trial comparing irinotecan in combination with either the Nordic bolus 5FU and folinic acid schedule or the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer [abstract 597]. Eur J Cancer Suppl 2005 Oct; 3 (2): 167Google Scholar
  20. 20.
    Fischer Von Weikersthal L, Schalhorn A, Quietzsch D, et al. Randomised comparison of 5-FU/folinic acid plus irinotecan and irinotecan plus oxaliplatin in firstline therapy of metastatic colorectal cancer: the fire-trial [abstract 598]. Eur J Cancer Suppl 2005 Oct; 3 (2): 167Google Scholar
  21. 21.
    Falcone A, Brunetti IM, Benedetti G, et al. Improved activity with irinotecan, oxaliplatin and infusional 5-FU/LV compared with FOLFIRI in metastatic colorectal cancer: results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest [abstract 599]. Eur J Cancer Suppl 2005 Oct; 3 (2): 167–8Google Scholar
  22. 22.
    Punt C, Douma J, Honkoop A, et al. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer, an interim safety analysis: a Dutch Colorectal Cancer Group phase III study [abstract 600]. Eur J Cancer Suppl 2005 Oct; 3 (2): 168Google Scholar
  23. 23.
    Arkenau H, Kubicka S, Greil R, et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin versus capecitabine plus oxaliplatin as first line treatment of metastatic colorectal carcinoma: results of the safety and efficacy analysis [abstract 601]. Eur J Cancer Suppl 2005 Oct; 3 (2): 168Google Scholar
  24. 24.
    Georgoulias V, Berry S, Di Bartolomeo M, et al. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for mCRC — First BEATrial [abstract 602]. Eur J Cancer Suppl 2005 Oct; 3 (2): 168–9Google Scholar
  25. 25.
    Ault K, GARDASIL TM Phase III Steering Committee. Prophylactic use of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine reduces cervical intraepithelial neoplasia 2/3 and adeocarcinoma in situ risk [abstract PS10]. Eur J Cancer Suppl 2005 Oct; 3 (4): 11CrossRefGoogle Scholar
  26. 26.
    Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer [abstract PS11]. Eur J Cancer Suppl 2005 Oct; 3 (4): 12CrossRefGoogle Scholar
  27. 27.
    O’Byrne KJ, Bonomi P, Paz-Ares L, et al. Paclitaxel poliglumex vs. docetaxel for the second-line treatment of non-small cell lung cancer: the STELLAR 2 phase III study [abstract PS13]. Eur J Cancer Suppl 2005 Oct; 3 (4): 14CrossRefGoogle Scholar
  28. 28.
    Van Meerbeeck J. A randomized trial of radical surgery versus thoracic radiotherapy in patients with stage IIIA-N2 non-small cell lung cancer after response to induction chemotherapy (EORTC 08941) [abstract 1120]. Eur J Cancer Suppl 2005 Oct; 3 (2): 323Google Scholar
  29. 29.
    Smith I, Groen HJM, Van Meerbeeck J, et al. The impact of giving neo-adjuvant chemotherapy for patients with non-small cell lung cancer: data from the MRC LU22/NVALT/EORTC 08012 randomised clinical trial [abstract 1121]. Eur J Cancer Suppl 2005 Oct; 3 (2): 323–4Google Scholar
  30. 30.
    O’Brien M, Oldham F. Paclitaxel poliglumex vs. gemcitabine or vinorelbine for the treatment of performance status 2 patients with chemotherapy-naive advanced non-small cell lung cancer: the STELLAR 4 phase III study [abstract 1122]. Eur J Cancer Suppl 2005 Oct; 3 (2): 324Google Scholar
  31. 31.
    Crawford J, Swanson P, Prager D, et al. Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for the first line advanced non-small cell lung cancer: a primary analysis [abstract 1123]. Eur J Cancer Suppl 2005 Oct; 3 (2): 324Google Scholar
  32. 32.
    Ranson M, Bodkin D, Govindan R, et al. Results of a randomized, double-blind phase II trial of ZD6474 versus gefitinib in patients with NSCLC [abstract 1124]. Eur J Cancer Suppl 2005 Oct; 3 (2): 324–5Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Andrea Bothwell
    • 1
  1. 1.Adis International LtdAucklandNew Zealand

Personalised recommendations